As the popularity of GLP-1 receptor agonists (GLP1ra)—such as semaglutide and tirzepatide—continues to skyrocket for the treatment of obesity and type 2 diabetes, the medical community is grappling with the downstream effects of these drugs on elective surgery. A landmark study published in the April issue of Plastic and Reconstructive Surgery®, the official journal of the American Society of Plastic Surgeons (ASPS), offers a critical, nuanced look at how these medications influence outcomes for patients undergoing abdominal panniculectomy—a primary procedure for removing excess skin following massive weight loss.
The research, led by Dr. Zachary Andrew Koenig of the West Virginia University School of Medicine, suggests that while these drugs do not appear to pose an overall increase in major surgical risk, they do exert "subtle" and specific effects on the complex biological process of wound healing.
Main Facts: Decoding the GLP-1 and Surgery Nexus
The core of the issue lies in the intersection of two rapidly growing fields: the pharmacological management of metabolic health and the surgical reconstruction of the body after weight loss. Panniculectomy, a procedure dedicated to excising the "pannus"—the hanging apron of skin and fat often left behind after significant weight reduction—is technically demanding. It involves extensive tissue mobilization, which makes wound healing a high-priority concern for plastic surgeons.
Dr. Koenig’s study analyzed 373 patients who underwent non-bariatric panniculectomy between 2013 and 2023. The researchers specifically isolated these patients from those undergoing concurrent hernia or bariatric procedures to ensure the results reflected the impact of the medication on the panniculectomy itself.
The findings highlight a "complex and nuanced" landscape:
- Delayed Healing: Patients on GLP-1 medications were significantly more likely to experience delayed wound healing (18.5% compared to 7.5% in the non-GLP-1 group).
- Seroma Reduction: Interestingly, the study found that GLP-1 users had a lower incidence of seroma—the problematic fluid collection that often occurs under surgical incisions—at 4.9% versus 14.0%.
- Overall Safety: The researchers found no statistically significant differences between the two groups regarding wound dehiscence (reopening of the incision), surgical site infections, or readmission rates.
Chronology: A Decade of Tracking Surgical Trends
To understand the current clinical landscape, the research team performed a ten-year retrospective analysis. The timeline of this data collection provides a bird’s-eye view of how the prevalence of GLP-1 usage has shifted within the plastic surgery patient demographic.
2013–2018: The Pre-GLP-1 Surge Era
During the first half of the study period, the use of GLP-1 receptor agonists among patients seeking body contouring was relatively low. These medications were primarily reserved for patients with strictly defined type 2 diabetes, and the "off-label" use for weight management had not yet reached the cultural or clinical zeitgeist.
2019–2021: The Turning Point
As clinical trials began to showcase the profound weight-loss benefits of the newer generation of GLP-1 agonists, plastic surgeons began to see a change in their patient profiles. Many patients arrived in the clinic already on these therapies, having used them as a bridge to reach their target body weight before undergoing skin removal. During this period, the West Virginia University team noted a "sharp increase" in prescription rates among their surgical candidates.
2022–2023: The Modern Clinical Landscape
By the end of the study period, 21.7% of the total cohort were active users of GLP-1 medications. This rapid rise highlights the urgency of the study: surgeons are now frequently operating on patients whose metabolic processes are being actively modulated by these powerful agents. The data collected during this final phase allowed the researchers to compare outcomes in a statistically robust way, providing a clearer picture than anecdotal evidence could offer.
Supporting Data: Examining Patient Profiles
One of the most critical aspects of the study was the comparison of baseline characteristics between those on GLP-1 therapy and those who were not. This analysis helps distinguish whether the observed outcomes were due to the medication itself or simply a reflection of the patient’s underlying health status.
The study revealed that patients using GLP-1 medications tended to be more medically complex. They were statistically more likely to have:
- Type 2 Diabetes: A known factor that can complicate microvascular circulation.
- Hypertension: Which impacts blood pressure management during and after anesthesia.
- Chronic Obstructive Pulmonary Disease (COPD): Which influences oxygenation—a vital component of wound healing.
Crucially, however, the Body Mass Index (BMI) between the two groups was not significantly different. This is a vital finding, as it suggests that the differences in wound healing outcomes are likely independent of the patient’s weight and more closely linked to either the medication’s physiological effects or the comorbid conditions associated with the patient’s history.
The reduction in seroma—the fluid collection—is perhaps the most counterintuitive finding. The researchers posit that the medication might be influencing inflammatory responses or lymphatic drainage in ways that are not yet fully understood, potentially creating a "protective" effect against fluid buildup while simultaneously slowing the closure of the skin itself.
Official Responses and Clinical Perspectives
The medical community has greeted the study with a blend of relief and caution. Dr. Zachary Andrew Koenig and his colleagues emphasize that while the findings are encouraging, they should not be viewed as a "green light" for lax perioperative management.
"Our findings suggest that while GLP1ra therapy does not appear to increase major surgical risk, it may affect specific aspects of healing that warrant proactive management," the authors stated.
The American Society of Plastic Surgeons (ASPS) has been vocal about the need for standardized guidelines. Because West Virginia has one of the highest rates of GLP-1 prescriptions in the United States, the findings from this study are particularly representative of the "new normal" for many regional plastic surgery centers.
Plastic surgeons are now increasingly involved in the "optimization" phase of care. This involves deciding whether a patient should remain on their GLP-1 medication through the surgery or undergo a "washout" period—stopping the medication for a specific number of days prior to anesthesia. Currently, there is no universal consensus, and this study highlights that a one-size-fits-all approach may be insufficient.
Implications: Navigating the Future of Body Contouring
The implications of this research are wide-reaching for both surgeons and patients. As we look toward the future, the integration of GLP-1 therapy into the surgical pathway will require a more granular approach to patient care.
1. Preoperative Risk Stratification
Surgeons must now add "medication history" as a key variable in their risk assessment models. The knowledge that GLP-1 patients have a higher risk of delayed wound healing allows surgeons to adjust their counseling. Patients can be warned of a longer recovery time, and surgeons may choose to extend the use of specialized wound care products or increase the frequency of postoperative check-ups.
2. Tailoring Surgical Technique
The reduced incidence of seromas in GLP-1 users might lead to changes in surgical techniques. Surgeons might re-evaluate the need for certain types of drains or internal sutures if they know a patient is on GLP-1 therapy, effectively tailoring the surgery to the patient’s specific metabolic profile.
3. The Need for Formalized Guidelines
Perhaps the most significant takeaway is the clarion call for formal, evidence-based guidelines. The "rapidly evolving clinical landscape" described by the researchers is moving faster than the current medical literature can keep up with. Formal, society-wide guidelines on how to manage GLP-1 usage before and after surgery—including whether to pause, when to resume, and how to monitor for specific complications—are now an urgent necessity.
4. A Multi-Disciplinary Approach
The study underscores the necessity of a collaborative approach between primary care physicians, endocrinologists, and plastic surgeons. As these medications become a standard part of metabolic health, the plastic surgeon can no longer act in a vacuum. A patient’s GLP-1 regimen must be managed as part of a holistic surgical plan that considers the patient’s entire metabolic health.
In conclusion, while the study by Dr. Koenig and his team does not provide a definitive "yes" or "no" to the safety of GLP-1 use in body contouring, it provides the essential data points required to move toward a more intelligent, evidence-based standard of care. By acknowledging the "subtle effects" on wound healing, the plastic surgery community is better equipped to manage patient expectations, improve outcomes, and continue to provide safe, effective body contouring for the growing population of patients who have achieved massive weight loss.
As research continues, the goal remains clear: to ensure that the medical advancements in weight loss are supported—not hindered—by the surgical procedures that finalize the patient’s journey.
About the Author
